Drug Profile

APG 273

Alternative Names: APG-273; APG-777+APG-333

Latest Information Update: 19 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Apogee Therapeutics
Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
Mechanism of Action Interleukin 13 inhibitors; Thymic stromal lymphopoietin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

11 May 2026 Apogee Therapeutics plans a clinical trial for respiratory disorders in 2026
10 Nov 2025 Preclinical trials in Asthma in USA (Parenteral) (Apogee Therapeutics pipeline; November 2025)
10 Nov 2025 Preclinical trials in Chronic obstructive pulmonary disease in USA (Parenteral) (Apogee Therapeutics pipeline; November 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com